Ursodeoxycholic acid treatment in a rat model of cancer cachexia

[1]  D. Kelleher,et al.  Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators. , 2011, Journal of medicinal chemistry.

[2]  Stephan von Haehling,et al.  An overview of sarcopenia: facts and numbers on prevalence and clinical impact , 2010, Journal of cachexia, sarcopenia and muscle.

[3]  Stephan von Haehling,et al.  Cachexia as a major underestimated and unmet medical need: facts and numbers , 2010, Journal of cachexia, sarcopenia and muscle.

[4]  S. Anker,et al.  Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle , 2010, Journal of cachexia, sarcopenia and muscle.

[5]  G. Kolios,et al.  A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. , 2010, European journal of pharmacology.

[6]  Y. Chrétien,et al.  Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study , 2010, European journal of gastroenterology & hepatology.

[7]  J. O’Sullivan,et al.  Bile acids modulate the Golgi membrane fission process via a protein kinase Ceta and protein kinase D-dependent pathway in colonic epithelial cells. , 2010, Carcinogenesis.

[8]  G. Jenkins,et al.  The role of secondary bile acids in neoplastic development in the oesophagus. , 2010, Biochemical Society transactions.

[9]  Jesse D. Martinez,et al.  Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. , 2009, Biochimica et biophysica acta.

[10]  M. Tisdale.  Mechanisms of cancer cachexia. , 2009, Physiological reviews.

[11]  M. Tisdale.  Catabolic mediators of cancer cachexia , 2008, Current opinion in supportive and palliative care.

[12]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[13]  Chuanshu Huang,et al.  The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. , 2007, Current cancer drug targets.

[14]  Takuji Tanaka,et al.  Ursodeoxycholic Acid versus Sulfasalazine in Colitis-Related Colon Carcinogenesis in Mice , 2007, Clinical Cancer Research.

[15]  Y. Volkov,et al.  Ursodeoxycholic acid inhibits interleukin beta 1 and deoxycholic acid‐induced activation of NF‐κB and AP‐1 in human colon cancer cells , 2006 .

[16]  Y. Volkov,et al.  Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-kappaB and AP-1 in human colon cancer cells. , 2006, International Journal of Cancer.

[17]  K. Shiraki,et al.  Different effects of bile acids, ursodeoxycholic acid and deoxycholic acid, on cell growth and cell death in human colonic adenocarcinoma cells. , 2005, International journal of molecular medicine.

[18]  R. Löfberg,et al.  Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. , 2004, Anticancer research.

[19]  A. Bauhofer,et al.  Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxis , 2001, Langenbeck's Archives of Surgery.

[20]  E. Heathcote.  Management of primary biliary cirrhosis , 2000 .

[21]  E. Heathcote.  Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. , 2000, Hepatology.

[22]  K. Terada,et al.  Prevention of N‐Methylnitrosourea‐induced Colon Tumorigenesis by Ursodeoxycholic Acid in F344 Rats , 1998, Japanese journal of cancer research : Gann.

[23]  E. Gerner,et al.  Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. , 1998, Nutrition and cancer.

[24]  A. Billiau,et al.  Cytokines and cachexia. , 1997, Nutrition.

[25]  J. Lord,et al.  Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids , 1995, International journal of cancer.

[26]  A. Bhattacharyya,et al.  Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. , 1994, Cancer research.

[27]  L. Tessitore,et al.  Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. , 1993, The Journal of clinical investigation.